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ERYTHROPOIESIS AFTER NONMYELOABLATIVE STEM-CELL
TRANSPLANTATION IS NOT IMPAIRED BY INADEQUATE
ERYTHROPOIETIN PRODUCTION AS OBSERVED AFTER
CONVENTIONAL ALLOGENEIC TRANSPLANTATION
F. BARON,1 G. FILLET,1 AND Y. BEGUIN1,2
Background. It is now well established that after
conventional allogeneic hematopoietic stem-cell trans-
plantation (HSCT), erythropoietic recovery is impaired
because erythropoietin (Epo) production remains inad-
equate for prolonged periods of time. However, erythro-
poietic reconstitution after nonmyeloablative SCT
(NMSCT) has never been characterized.
Methods. Twelve patients received a nonmyeloabla-
tive conditioning regimen consisting of 2 Gy total body
irradiation (TBI) alone (n6), 2 Gy TBI and fludara-
bine (n3), or cyclophosphamide and fludarabine
(n3), followed by transplantation of allogeneic pe-
ripheral blood stem cells. Graft-versus-host-disease
(GvHD) prophylaxis was carried out with mycopheno-
late mofetil (from day 1 to day 28) plus cyclosporine
(from day 1 to day 120 or longer in case of chronic
GvHD). Erythropoiesis was quantitated by soluble
transferrin receptor (sTfR) levels, and the adequacy of
Epo production was evaluated by the observed-to-pre-
dicted Epo ratio (O/P Epo).
Results. Mean sTfR levels decreased following the
conditioning regimen but remained well within the
normal range throughout the posttransplant period.
The O/P Epo ratio presented an initial surge quite
similar to that observed after conventional condition-
ing. Thereafter, the O/P Epo ratio normalized rapidly,
and Epo levels remained adequate during the whole
observation period.
Conclusion. Contrarily to what is observed after my-
eloablative transplant, Epo levels remained adequate
after NMSCT, resulting in normal erythropoiesis.
These results suggest that the administration of eryth-
ropoietin therapy (rHuEpo) could be less effective af-
ter NMSCT than after conventional allogeneic
transplant.
Allogeneic hematopoietic stem-cell transplantation
(HSCT) is an effective treatment for selected hematologic
malignancies (1, 2). Its curative potential is in part achieved
through an immune-mediated destruction of malignant cells
by donor lymphocytes termed the graft-versus-leukemia
(GVL) effect (2–7). However, because of its toxicity, conven-
tional allogeneic HSCT is restricted to younger and fitter
patients (8). Therefore, several groups have developed the
concept of nonmyeloablative stem-cell transplantation
(NMSCT), in which the main mechanism of tumor eradica-
tion is shifted from high-dose cytotoxic agents to the GVL
effect (9, 10). After extensive preclinical studies (11–15), the
Seattle team developed a nonmyeloablative HSCT approach
combining 2 Gy total body irradiation (TBI)90 mg/m2 flu-
darabine as a conditioning regimen and postgrafting immu-
nosuppression with cyclosporine (CsA) and mycophenolate
mofetil (MMF). This approach was recently shown to be
feasible even in elderly or sick patients who were ineligible
for a conventional transplant (9, 16). Because of the mild
conditioning regimen given and the use of peripheral blood
stem cells (PBSC) as the source of hematopoietic stem cells,
posttransplant myelosuppression remained modest and tran-
sient (9, 16). Moreover, the Seattle team recently demon-
strated that both red-blood-cell (RBC) and platelet transfu-
sion requirements were reduced in NMSCT compared with
conventional PBSC transplant recipients (10).
Erythropoietin (Epo) is the critical regulatory factor of
erythropoiesis (17). In patients with normal kidney function,
serum Epo levels increase exponentially when an anemia
develops. After high-dose chemotherapy, serum Epo levels
first rapidly increase to disproportionately high levels for 1 to
3 weeks, with peak values usually observed in the first week
after the conditioning regimen (18–27). However, after allo-
geneic SCT, the Epo response to anemia then generally be-
comes impaired, resulting in inappropriately low Epo levels
for the degree of anemia and prolonged anemia (21, 24). This
is specific for allogeneic transplants because serum Epo lev-
els remain adequate throughout the posttransplant course in
recipients of an autologous marrow or PBSC transplant (19,
20, 22, 23, 25–28). This defect in Epo production has been
attributed to the use of cyclosporine (29), which does not
affect the expression of the Epo gene but causes an inhibition
of Epo secretion (30). However, other factors such as graft-
versus-host disease (GvHD) (20, 24, 28, 31) or cytomegalovi-
rus (CMV) infection (20, 28) may also contribute to it. On the
basis of these findings, it is not surprising that erythropoietin
therapy (rHuEpo) shows some efficacy in the early posttrans-
plant period after allogeneic (32, 33) but not autologous
transplantation (32, 33), but is remarkably efficient when it
is started after day 35 postallogeneic transplantation (34).
However, erythropoietic recovery after a nonmyeloablative
transplant has not been well characterized, and it is not
known whether rHuEpo could enhance erythroid function in
this setting. In this study, we examined the reconstitution of
erythropoiesis in 12 recipients of a nonmyeloablative trans-
plant (NMSCT group, n12). Results were compared with a
group of conventional bone-marrow-transplant (BMT) recip-
ients previously reported (BMT group, n47) (25) and with a
group of patients undergoing a standard myeloablative PBSC
transplant (PBSC group, n6).
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We studied 12 patients (Table 1) receiving a PBSC transplant
after a nonmyeloablative conditioning regimen (16). Written in-
formed consent was obtained from patients to draw blood samples for
the study. Conditioning (Table 1) consisted of 2 Gy single dose TBI
alone on day 0 (n6). For patients not heavily pretreated or for
unrelated transplants, TBI was combined with 30 mg/m2/day flu-
darabine for 3 days (n3). The first patient was an exception to this
rule because the high rejection rate in chronic myeloid leukemia
patients with the original Seattle protocol was not yet published
when she was treated. Finally, 3 patients received a combination of
fludarabine and cyclophosphamide at 1 g/m2 per day for 3 days
(Fluda-Cy) because they had previously received 12 Gy TBI as con-
ditioning regimen for an autotransplant (Table 1). Posttransplant
immunosuppression was carried out orally with cyclosporine (CsA
twice daily dose adjusted to achieve whole blood levels in the range
of 300–400 ng/mL from day 1 to day 120 or longer in case of
alternative donor or chronic GvHD) and MMF (15 mg/kg twice daily
from day 1 to day 28). The trigger values for RBC and platelet
transfusion were 8.0 g/dL and 15 109/L, respectively. Granulocyte
(G)-CSF (5 g/kg per day) was administered when the granulocyte
count was below 1.0109/L. The diagnosis and grading of acute and
chronic GvHD was established as previously reported (16). Polymer-
ase chain reaction (PCR) for CMV was performed weekly until day
100 and every 2 to 4 weeks thereafter. Patients with a positive PCR
received preemptive ganciclovir for a minimum of 4 weeks and gen-
erally up to day 100.
Laboratory Analyses
CsA levels were measured by chromatography. Complete blood
counts were determined in a Technicon H2 cell counter (Bayer,
Tarrytown, NJ). Serum Epo levels were measured by a commercially
available radioimmunoassay (Incstar Corp., Stillwater, MN). On the
basis of regression equations obtained in appropriate reference sub-
jects between hematocrit (Hct) on the one hand and log (Epo) on the
other, predicted log (Epo) values were derived for each Hct, and O/P
ratios of observed–predicted Epo values were calculated (31). The
mean (standard deviation) Epo O/P ratio in a cohort of 31 normal
donors was 1.030.08. Serum-soluble transferrin receptor (sTfR), a
quantitative measure of total erythropoietic activity, was measured
by a commercially available ELISA (R&D, Minneapolis, MN). Nor-
mal values range from 3,000 to 7,000 g/L.
Statistical Analysis
Unpaired Student’s t tests were used to compare biologic variables
in two groups. Welsh’s correction was used in case of unequal vari-
ance. The probability of GvHD and CMV reactivation were studied
by life-table analyses, and Wilcoxon rank tests were used for com-
parisons between groups. Statistical analyses were carried out with
Graphpad Prism (Graphpad Software, San Diego, CA).
RESULTS
Clinical Data
Mean CsA blood levels were 416143 ng/mL on day 14,
308116 ng/mL on day 42, and 20866 ng/mL on day 100,
respectively (Fig. 1). The actuarial 150-day incidence of grade
I-IV (II-IV) acute GvHD was 41% (25). The actuarial 150-day
incidence of CMV reactivation was 58%.
TABLE 1. Patient characteristics
Characteristic NMSCT(n  12)
PBSC
(n  6)
Median age (years) 58 38
Sex (M/F) 10/2 5/1
Disease
Lymphoma 6 1
Acute leukemia 2 3
Chronic myeloid leukemia 2 1
Renal-cell carcinoma 1 0
Chronic lymphocytic leukemia 1 0
Aplastic anemia 0 1
Disease status
Untreated 2 3
CR1 or CR2 4 3





2 Gy TBI 6 0
Fludarabine and 2 Gy TBI 3 0
Fludarabine and Cyclophosphamide 3 0
Donor
Sibling, HLA identical 7 5
Sibling, 1 mismatch 3 1
Unrelated, HLA identical 2 0










CyA and MMF 12 0
CyA and MTX 0 6
Grade II-IV acute GvHD
Yes 4 4
No 8 2
NMSCT, nonmyeloablative stem-cell transplantation; PBSC, pe-
ripheral blood stem cells; TBI, total body irradiation; HLA, human
leukocyle antigen; BM, bone marrow; GMV, cytomegalovirus; GvHD,
graft-versus-host disease; MMF, mycophenolate mofetil; MTX, meth-
otrexate.
FIGURE 1. Cyclosporine blood levels in the nonmyeloablative
stem-cell transplantation (NMSCT) group. HSCT, hematopoi-
etic stem cell transplantation.
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Erythropoietic Activity
NMSCT recipients were compared with conventional BMT
recipients. There was little difference in Hemoglobin (Hb)
levels after transplantation because patients in the BMT
group were supported by RBC transfusions when their Hb
fell below 10 g/dL (many transfusions), but patients in the
NMSCT group maintained better Hb levels, with few trans-
fusions when the Hb was less than 8 g/dL (Fig. 2). After
conventional BMT, sTfR levels decreased sharply after the
conditioning regimen to a minimum of 2040740 on day 14
then increased up to day 60 but decreased again thereafter
(P0.02 between days 60 and 150) (Fig. 3). The evolution was
very similar in the conventional PBSC group with a nadir of
1000350 g/L on day 14 followed by a recovery through day
80 and a secondary decrease thereafter. In the NMSCT
group, sTfR levels were 65202120 g/L before conditioning
and decreased significantly (P0.007) to a minimum of
40001710 g/L on day 10 but remained consistently above
5000 g/L thereafter (Fig. 3). The initial sTfR decrement was
significantly smaller than after conventional HSCT, and
sTfR values never fell below the normal range.
Serum Erythropoietin Levels
After NMSCT, serum Epo levels peaked on day 0 with a
mean O/P Epo of 1.120.11 (P0.0057 compared with O/P
Epo in 31 healthy donors), which was very similar to the O/P
Epo of 1.110.20 after conventional BMT (Fig. 4). Although
O/P Epo after conventional BMT between days 14 and 180
were significantly lower than in normal subjects (P0.05 to
P0.001) and significantly decreased compared with pre-
transplant values (P0.02 to P0.001), Epo production was
adequate throughout the posttransplant course after
NMSCT (Fig. 4). Moreover, O/P Epo ratio remained signifi-
cantly higher in the NMSCT group compared with the BMT
group from day 28 to day 180 (Fig. 4). Indeed, the average
O/P Epo of all samples obtained between days 14 and 180 in
all NMSCT recipients (0.990.19, n105) did not signifi-
cantly differ from the O/P Epo of normal subject (1.030.08,
n31). Although the number of observations after conven-
tional PBSC transplant was too low for differences to reach
statistical significance at any particular time point, pooled
O/P Epo values for the entire posttransplant course were
significantly lower than in the NMSCT group (P0.0121).
DISCUSSION
Elevated serum Epo levels are observed transiently after
intensive conditioning regimens without concomitant
changes in Hb (18-27, 35, 36). The peak Epo values are
FIGURE 2. Hemoglobin (Hb) levels (meanSEM) after con-
ventional bone marrow transplant (BMT) or NMSCT. P val-
ues are given for comparisons between the two groups,
*P<0.05.
FIGURE 3. Erythropoietic activity, as assessed by soluble
transferrin receptor (sTfR) levels (meanSEM) after NMSCT,
compared with conventional BMT. (horizontal lines) 95% con-
fidence interval of sTfR in normal subjects. P values are
given for comparisons between the two groups: *P<0.05,
**P<0.01, ***P<0.001.
FIGURE 4. Epo production, as assessed by O/P Epo
(meanSEM), after NMSCT as compared with conventional
BMT. (horizontal lines) 95% confidence limits of observed-to-
predicted erythropoietin ratio (O/P Epo) in subjects with
adequate Epo production. P values are given for comparisons
between the two groups: *P<0.05, **P<0.01, ***P<0.001.
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usually observed 0 to 7 days after transplant, at the time of
the nadir of erythropoietic activity. There is now substantial
evidence that serum Epo levels partly depend on the rate of
Epo use by Epo receptor-bearing erythroid precursors (27,
37). Therefore, severe myelosuppression following the condi-
tioning regimen could disrupt the usual Epo degradation
pathway and provoke a surge of serum Epo concentration
through prolonged Epo life span (27). However, the NMSCT
recipients in the current study received a much milder con-
ditioning regimen and yet still experienced a significant drop
in erythropoietic activity (Fig. 3), resulting in some decrease
in Hb levels (Fig. 2). Although the level of erythropoiesis
remained well within the normal range, the surge in serum
Epo levels was quite similar to that observed after myeloab-
lative conditioning (Fig. 4). Indeed, it has been suggested
that such changes in serum Epo levels could relate to change
in the rate of production rather than in the rate of use (38).
With marrow recovery after a myeloablative transplant,
Epo levels progressively return to an appropriate range, and
the duration of this correction phase inversely correlates
with the speed of engraftment (27). This is consistent with
increased Epo consumption by an expanding pool of erythroid
precursors. However, animal experiments indicate that mar-
row accumulation of Epo is minimal, and that Epo life span
is not significantly influenced by erythropoietic activity (39,
40). Indeed, experimental data suggest that variations in
plasma Epo levels during periods of rapidly expanding eryth-
ropoiesis are the result of decreased production rather than
enhanced use (38), but the precise mechanisms remain to be
elucidated.
After marrow recovery, endogenous Epo remains appropri-
ate for the degree of anemia in autologous transplant recip-
ients (19, 20, 22, 23, 25, 26) but rapidly becomes inadequately
low in patients receiving a myeloablative allogeneic trans-
plant (19–21, 24–26). This translates into erythropoietic ac-
tivity and Hb levels remaining quite low for several months
(25). This defect in Epo production has been partly attributed
to the use of CsA (29, 30), which does not affect the expres-
sion of the Epo gene but causes an inhibition of Epo secretion
(30). However, other factors such as acute GvHD (20, 24, 25,
28) or CMV infection (20, 28) have also been involved. We
have recently shown that starting rHuEpo around day 35
after conventional allogeneic HSCT resulted in major re-
sponses in more than 90% of the patients (34), demonstrating
that rHuEpo substitution at the time of marrow recovery can
accelerate erythropoietic reconstitution that would otherwise
remain impaired because Epo levels remain inadequate for
prolonged periods of time.
Interestingly, our NMSCT recipients did not experience
inappropriately low Epo levels for the degree of anemia nor
the subsequent decrease in erythropoietic activity. Rather,
Epo O/P ratios and sTfR levels were constantly well within
the normal range. The reasons for this discrepancy with
conventional transplants remain unclear. The use of PBSC
instead of marrow as the source of stem cells cannot be
incriminated because the control group of conventional PBSC
transplants behaved similarly to the conventional BMT re-
cipients. NMSCT recipients received CsA at least to day 120
after the transplant, and blood CsA levels were quite high.
This could indicate that CsA is not the primary cause for the
inappropriately low Epo levels observed after conventional
transplant. Similarly, the rate of CMV reactivation in our
NMSCT patients (58%) was comparable with that observed
in our conventional BMT recipients (50%) (25).
Acute GvHD has also been associated with the defect in
Epo production. The incidence of acute GvHD was lower in
our NMSCT patient (41%) compared with our BMT group
(64%) (25). This is in accordance with the generally lower
incidence and severity of acute GvHD observed after NMSCT
(16). This relatively low incidence of acute GvHD may partly
explain their appropriate levels of serum Epo. It has been
suggested that the persistence of recipient hematopoietic or
immune cells (mixed chimerism) after NMSCT could contrib-
ute to improve donor-versus-host tolerance (41). One could
speculate that such tolerance toward host tissues would also
apply to host Epo-producing cells either directly or through
more limited production of inhibitory cytokines (42).
In conclusion, contrary to what is observed after conven-
tional myeloablative HSCT, serum Epo levels remain ade-
quate throughout the posttransplant course after NMSCT.
These results suggest that the administration of rHuEpo
could be less effective after NMSCT than after conventional
allogeneic transplant.
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